Abstract
MammaPrint® (MP) is a 70-gene based assay that stratifies early-stage breast cancer patients into low and high-risk of relapse. Blueprint® (BP) is a 80-gene based assay that stratifies breast cancer patients in 3 molecular subtypes (Basal, Luminal and HER2). Previously, we showed that the MP genes reflect the six hallmarks of cancer (HoC) as defined by Hanahan and Weinberg (Tian et al 2011). Later, these were extended to ten HoC (Hanahan et al. 2011). In this study we annotated the MP 70- and BP 80-genes with respect to the ten HoC.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
